[go: up one dir, main page]

AR133559A1 - INDOLE AND PYRROLILOPYRIDINE DERIVATIVES AS GPR17 MODULATORS - Google Patents

INDOLE AND PYRROLILOPYRIDINE DERIVATIVES AS GPR17 MODULATORS

Info

Publication number
AR133559A1
AR133559A1 ARP240102167A ARP240102167A AR133559A1 AR 133559 A1 AR133559 A1 AR 133559A1 AR P240102167 A ARP240102167 A AR P240102167A AR P240102167 A ARP240102167 A AR P240102167A AR 133559 A1 AR133559 A1 AR 133559A1
Authority
AR
Argentina
Prior art keywords
pyrrolilopyridine
indole
derivatives
gpr17
formula
Prior art date
Application number
ARP240102167A
Other languages
Spanish (es)
Inventor
Andrew George Capacci
Ryan Evans
Thomas J Purgett
Zackary Stein
Zain Yousaf
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of AR133559A1 publication Critical patent/AR133559A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe un compuesto representado por la fórmula (1) o una sal farmacéuticamente aceptable de este. Las variables de la fórmula (1) se definen en la presente. Los compuestos de fórmula (1) son útiles para regular la actividad de GPR17 y para tratar trastornos y enfermedades mediados por GPR17 en humanos o no humanos.A compound represented by formula (1) or a pharmaceutically acceptable salt thereof is described. The variables of formula (1) are defined herein. Compounds of formula (1) are useful for regulating GPR17 activity and for treating GPR17-mediated disorders and diseases in humans or non-humans.

ARP240102167A 2023-08-15 2024-08-15 INDOLE AND PYRROLILOPYRIDINE DERIVATIVES AS GPR17 MODULATORS AR133559A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363532811P 2023-08-15 2023-08-15

Publications (1)

Publication Number Publication Date
AR133559A1 true AR133559A1 (en) 2025-10-08

Family

ID=92633059

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240102167A AR133559A1 (en) 2023-08-15 2024-08-15 INDOLE AND PYRROLILOPYRIDINE DERIVATIVES AS GPR17 MODULATORS

Country Status (3)

Country Link
AR (1) AR133559A1 (en)
TW (1) TW202515863A (en)
WO (1) WO2025038863A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI754702B (en) * 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 (aza)indole- and benzofuran-3-sulfonamides
WO2020254289A1 (en) * 2019-06-17 2020-12-24 Ucb Pharma Gmbh N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
WO2024017855A1 (en) * 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel isothiazol-3-yl and isoxazol-3-yl sulfonamide compounds

Also Published As

Publication number Publication date
WO2025038863A1 (en) 2025-02-20
TW202515863A (en) 2025-04-16

Similar Documents

Publication Publication Date Title
CL2022003326A1 (en) 4-oxo-3,4-dihydroquinazolinone compounds for the treatment of braf-associated diseases and disorders
AR121047A1 (en) MAP4K1 INHIBITORS
CO2024001367A2 (en) Antiviral compounds
DE59600105D1 (en) Use of adamantane derivatives to treat tinnitus
NO20076477L (en) New heterocyclic compounds as positive allosteric modulators of metabotropic glutamate receptors
CO5640104A2 (en) ACTIVE AMINOISOXAZOL DERIVATIVES AS QUINASA INHIBITORS
CO2021002976A2 (en) 5- to 7-membered heterocyclic amides as jak inhibitors
CY1124346T1 (en) CHROMANE, ISOCHROMANE, AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-APNHTIKOI ALLOSTERIC MODULATORS, THEIR COMPOSITIONS, AND USE THEREOF
CO2021014210A2 (en) Pyrrole compounds
CL2025001581A1 (en) n-Phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild-type c-kit kinase inhibitors for the treatment of urticaria
SA523451700B1 (en) Allosteric Chromenone Inhibitors of Phosphoinositide 3-Kinase (PI3K) for The Treatment of Disease
MX2024012967A (en) PYRIDINE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
CL2023000418A1 (en) Heteroaryl-substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
CL2021003139A1 (en) tricyclic compounds
AR133559A1 (en) INDOLE AND PYRROLILOPYRIDINE DERIVATIVES AS GPR17 MODULATORS
AR134040A1 (en) MRGPRX2 MODULATORS AND RELATED TREATMENT METHODS
AR133985A1 (en) KRAS INHIBITORS
ECSP014079A (en) SULFONAMIDE DERIVATIVES
ECSP23033180A (en) PYRAZOLE DERIVATIVES AS RET-KINASE INHIBITORS
MX2023011991A (en) Taar1 and serotonin modulators, and pharmaceutical compositions, and methods of use thereof.
MX2024008333A (en) COMPOUNDS FOR HAIR LOSS TREATMENT.
ECSP014078A (en) SULFONAMIDE DERIVATIVES
CL2022000147A1 (en) Pyridine derivatives as modulators of tmem16a for use in the treatment of respiratory conditions.
AR125594A1 (en) NOVEL NEGATIVE CYCLOPENTA[C]PYRROLE ALLOSTERIC MODULATORS FROM NR2B
AR043486A1 (en) DERIVATIVES OF 2- (DIAZA-BICICLO-ALQUIL) -PIRIMIDONA